Scientific Survey 2.0 - The Clinical Evidence + Scientific Survey
The insulin market is dominated by a few brands that are characterized by high treatment costs. There is much debate over whether the introduction of biosimilar products will help to increase access to safe, effective, and high-quality medications at a potentially lower cost.
Following the first phase of the scientific survey and apt responses received we intend further to continue the 2nd phase of the survey which is conducted to evaluate the perspective and evolving recommendations related to insulin therapy in the treatment of diabetes mellitus. The phase 2 survey information can help to further derive unbiased opinions from well-known diabetologists regarding the selection of insulin regimens and switching to interchangeable biosimilar products for best treatment outcomes in patients with diabetes mellitus.
1. To derive an unbiased approach in decision making and appropriate selection of insulin regimen to further find an affordable solution for patients with diabetes mellitus.
2. To collect unbiased valuable feedback from well-known diabetologists. The derived feedback shall enable us to compare the results of the various insulin regimens and interchangeable biosimilar products for best treatment outcomes.
3. To analyze results obtained from the survey, to address the topic of importance.
Diabetologists, Endocrinologists and Consulting Physicians.